Diagnostic utility of 68Ga- citrate and 18F-FDG PET/CT in sarcoidosis patients

Tetikkurt C., Yanardag H. , Sayman B. H. , Bilir M. , Tetikkurt S., Bilgic S. , ...Daha Fazla

Monaldi Archives for Chest Disease, cilt.90, sa.4, ss.729-737, 2020 (ESCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 90 Konu: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4081/monaldi.2020.1509
  • Dergi Adı: Monaldi Archives for Chest Disease
  • Sayfa Sayıları: ss.729-737


© Copyright: the Author(s), 2020Sarcoidosis is a chronic granulomatous disease of unknown etiology. The disease most commonly involves the lungs and the mediastinal lymph nodes while extrapulmonary organs such as the skin, eye, liver or spleen may also be comprised. Many imaging modalities have been used for the clinical evaluation of sarcoidosis patients, but all have been found to have certain drawbacks for a reliable diagnostic assessment due to the equivocal diagnostic results. This study was designed to determine the clinical trenchancy of simultaneous 68Ga-citrate PET/CT [Positron emission tomography with 68Ga-cit-rate (68Ga-citrate PET/CT)] and 18F-FDG PET/CT [Positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose (18F-FDG PET/CT)] imaging in sarcoidosis patients. The main goal was to evaluate sarcoidosis patients with respect to diagnosis, disease activity and organ involvement. A total of eight sarcoidosis patients with a comorbid disease suspicion were included in the study. Conventional clinical parameters used for the diagnosis and the activity of sarcoidosis including clinical, laboratory and computed tomography (CT) manifestations were compared with the 68Ga-cit-rate PET/CT findings. Concurrent 18F-FDG PET/CT was performed to verify the granulomatous inflammation of sarcoidosis and to determine coexisting malignant or other inflammatory diseases. Our study results revealed that 68Ga-citrate PET/CT imaging appears to be highly useful for the diagnosis, activity assessment and extrapulmonary organ involvement in sarcoidosis. Another crucial finding was the detection of extrapulmonary organ disease that are exceptionally involved, almost inaccessible by biopsy and that could not be otherwise displayed by other conventional imaging modalities. The third hallmark was the identification of a clinically asymptomatic and occult malignancy accompanying sarcoidosis that would not be detected in any way if synchronous 18F-FDG PET/CT had not been performed. Simultaneous application of 68Ga-citrate and 18F-FDG PET/CT may provide extremely useful data for the clinical evaluation of sarcoidosis patients in terms of the primary disease diagnosis, activity state, extrapulmonary organ involvement unachievable for biopsy and revealing occult malignant disorders that may coexist with sarcoidosis.